2.1
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older'.
Open for comments Open until Request commenting lead permission
We have updated this service so that members of the same organisation can now collaborate on a joint online response.
Read our blog to learn more.
Fenfluramine (Fintepla, UCB) is indicated for 'the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older'.
The dosage schedule is available in the summary of product characteristics for fenfluramine.
The list price for fenfluramine is £1,802.88 for the 120‑ml (2.2 mg/ml) bottle and £5,408.65 for the 360‑ml bottle (excluding VAT; BNF online accessed January 2024).
The company has a commercial arrangement. This makes fenfluramine available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation